Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
Posts: 43
Joined: Thu Aug 30, 2018 9:05 pm


Post by Gwikley » Thu Jun 18, 2020 1:39 am

Looking at the stats for new cases of MF in the US annually: 16.5 -18K per.
Wondering how JnJ saw Imetelstat as a "Billion dollar" pipeline drug.

Posts: 349
Joined: Fri Jul 20, 2018 5:13 pm

Re: Hindsight

Post by biopearl123 » Thu Jun 18, 2020 6:09 am

Gwickley, not sure what you mean but both Janssen and Dr. Scarlett estimate potential income in MF to be in that range. Also both kmall and Dr. Mascarenhas feel the actual numbers of cases are underestimated. bp

Posts: 5
Joined: Sun May 31, 2020 4:26 am

Re: Hindsight

Post by CKTC » Thu Jun 18, 2020 2:05 pm

Incyte’s Jakafi (ruxolitinib) did $1.7 billion in annual sales in 2019, principally in one indication - myelofibrosis. Incyte expects Jakafi to become a $3 billion brand eventually. There are no approved treatments for refractory myelofibrosis. This market will be lucrative for Geron if imetelstat is approved, and the company’s estimate of $1.5 billion in potential worldwide revenues is not unreasonable.

Post Reply